A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BEVERLY
- 14 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 14 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated